Clovis Oncology, Inc. (CLVS) Is At $50.92 Formed Wedge; 4 Bullish Analysts Covering IAMGOLD (IAG)

Among 13 analysts covering Iamgold Corp (NYSE:IAG), 4 have Buy rating, 3 Sell and 6 Hold. Therefore 31% are positive. Iamgold Corp had 44 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Sector Performer” rating by IBC given on Monday, June 27. The rating was upgraded by IBC on Wednesday, September 6 to “Outperformer”. Credit Suisse downgraded IAMGOLD Corporation (NYSE:IAG) on Friday, January 13 to “Underperform” rating. The stock of IAMGOLD Corporation (NYSE:IAG) has “Underperform” rating given on Wednesday, May 18 by Howard Weil. Canaccord Genuity upgraded IAMGOLD Corporation (NYSE:IAG) on Wednesday, October 19 to “Buy” rating. The rating was downgraded by Raymond James to “Underperform” on Friday, July 24. The rating was upgraded by Canaccord Genuity on Wednesday, January 17 to “Buy”. The firm has “Hold” rating given on Tuesday, November 24 by HSBC. Scotia Capital upgraded IAMGOLD Corporation (NYSE:IAG) on Thursday, May 11 to “Sector Perform” rating. The rating was maintained by BMO Capital Markets on Monday, December 18 with “Buy”. See IAMGOLD Corporation (NYSE:IAG) latest ratings:

17/01/2018 Broker: Canaccord Genuity Rating: Buy Upgrade
18/12/2017 Broker: BMO Capital Markets Rating: Buy New Target: $7.0 Maintain
10/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $7.0 Maintain
07/11/2017 Broker: BMO Capital Markets Rating: Buy New Target: $8.0 Maintain
17/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $7.5 Maintain
01/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $8.0 Maintain
29/09/2017 Broker: Canaccord Genuity Rating: Hold New Target: $8.07 Downgrade
15/09/2017 Broker: RBC Capital Markets Rating: Hold New Target: $7.5 Maintain
06/09/2017 Broker: IBC Old Rating: Neutral New Rating: Outperformer Upgrade
28/08/2017 Broker: RBC Capital Markets Rating: Hold New Target: $6.5 Maintain

Clovis Oncology, Inc. (CLVS) formed wedge down with $46.34 target or 9.00% below today’s $50.92 share price. Clovis Oncology, Inc. (CLVS) has $2.50 billion valuation. The stock increased 1.60% or $0.8 during the last trading session, reaching $50.92. About 1.71M shares traded or 36.99% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since February 10, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

The stock decreased 2.23% or $0.12 during the last trading session, reaching $5.26. About 5.78 million shares traded or 32.55% up from the average. IAMGOLD Corporation (NYSE:IAG) has risen 21.20% since February 10, 2017 and is uptrending. It has outperformed by 4.50% the S&P500.

IAMGOLD Corporation explores for, develops, and operates gold mining properties in North and South America, and West Africa. The company has market cap of $2.42 billion. It also explores for copper and silver. It has a 4.78 P/E ratio. The firm owns interest in the Rosebel gold mine located in north eastern Suriname, South America; Essakane gold mine in north-eastern Burkina Faso, West Africa; Westwood gold mine in southwestern Québec, Canada; and Sadiola, as well as Yatela gold mines situated in southwest Mali, West Africa.

Investors sentiment decreased to 1.44 in Q3 2017. Its down 0.37, from 1.81 in 2017Q2. It fall, as 48 investors sold Clovis Oncology, Inc. shares while 49 reduced holdings. 42 funds opened positions while 98 raised stakes. 47.46 million shares or 2.14% more from 46.46 million shares in 2017Q2 were reported. Columbus Circle Invsts has 213,674 shares. Profund Advsrs Llc holds 0.07% or 21,278 shares in its portfolio. Prudential Financial Inc reported 66,560 shares. Sei Invests owns 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 11,728 shares. State Board Of Administration Of Florida Retirement Systems reported 24,283 shares. Global X Mgmt reported 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Columbia Wanger Asset Management Ltd Liability Company invested in 581,660 shares or 0.71% of the stock. Redmile Grp Ltd accumulated 4.05% or 996,610 shares. Amalgamated Savings Bank reported 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Raymond James Advsr Inc stated it has 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Palo Alto Invsts Lc reported 11.56% in Clovis Oncology, Inc. (NASDAQ:CLVS). Cornerstone Capital Mngmt Lc invested in 0.01% or 17,333 shares. Chicago Equity Prns Lc holds 23,810 shares or 0.06% of its portfolio. Kingdon Cap Mngmt Llc owns 0.84% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 155,962 shares. Federated Pa holds 0% or 10,000 shares.

Since August 15, 2017, it had 0 buys, and 6 sales for $1.33 million activity. IVERS-READ GILLIAN C sold $192,480 worth of stock. 4,500 shares were sold by SPICKSCHEN THORLEF, worth $292,365.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 70% are positive. Clovis Oncology has $134 highest and $15 lowest target. $71.11’s average target is 39.65% above currents $50.92 stock price. Clovis Oncology had 56 analyst reports since September 10, 2015 according to SRatingsIntel. Suntrust Robinson initiated Clovis Oncology, Inc. (NASDAQ:CLVS) on Friday, August 5 with “Buy” rating. Chardan Capital Markets initiated the shares of CLVS in report on Tuesday, October 25 with “Sell” rating. The company was downgraded on Tuesday, November 17 by WallachBeth Capital. The company was maintained on Monday, February 5 by Leerink Swann. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Neutral” rating by Chardan Capital Markets on Tuesday, December 20. The company was upgraded on Wednesday, May 17 by JP Morgan. Suntrust Robinson maintained the shares of CLVS in report on Friday, September 23 with “Buy” rating. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, September 21. The stock has “Buy” rating by Leerink Swann on Monday, September 18. WallachBeth Capital maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Wednesday, December 21 with “Hold” rating.